Lixte Biotechnology (NASDAQ:LIXT) Stock Price Down 4.6% – Here’s What Happened

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was down 4.6% on Monday . The stock traded as low as $3.34 and last traded at $3.4450. Approximately 7,821 shares changed hands during trading, a decline of 83% from the average daily volume of 46,207 shares. The stock had previously closed at $3.61.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Lixte Biotechnology in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Lixte Biotechnology Stock Performance

The company has a market cap of $44.50 million, a price-to-earnings ratio of -3.09 and a beta of 0.93. The stock’s fifty day moving average is $3.00 and its two-hundred day moving average is $3.65.

Institutional Investors Weigh In On Lixte Biotechnology

Institutional investors and hedge funds have recently made changes to their positions in the business. Axxcess Wealth Management LLC acquired a new stake in shares of Lixte Biotechnology in the 4th quarter worth about $54,000. XTX Topco Ltd acquired a new stake in shares of Lixte Biotechnology in the 4th quarter worth about $57,000. Geode Capital Management LLC raised its holdings in shares of Lixte Biotechnology by 25.9% in the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock worth $205,000 after acquiring an additional 10,722 shares during the last quarter. DRW Securities LLC raised its holdings in shares of Lixte Biotechnology by 11.6% in the 4th quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock worth $213,000 after acquiring an additional 5,645 shares during the last quarter. Finally, Federation des caisses Desjardins du Quebec raised its holdings in shares of Lixte Biotechnology by 83.6% in the 4th quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock worth $367,000 after acquiring an additional 42,530 shares during the last quarter. Institutional investors and hedge funds own 5.10% of the company’s stock.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.